title: Progressive Multifocal Leukoencephalopathy.
abstract: Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease with significant morbidity and mortality and no effective, targeted therapies. It is most often observed in association with abnormalities of cell-mediated immunity, in particular human immunodeficiency virus (HIV) infection, but also occurs in association with lymphoproliferative diseases, certain immunosuppressive and immunomodulatory regimens, and other conditions. The etiologic agent of PML is a small, ubiquitous polyomavirus, the JC virus (JCV, also known as JCPyV), for which at least 50% of the adult general population is seropositive. PML results when JCV replicates within cerebral oligodendrocytes and astrocytes, leading to oligodendrocyte death and demyelination. Unfortunately, no treatments have been convincingly demonstrated to be effective, though some have been employed in desperation; treatment otherwise includes attempts to restore any immune system defect, such as the withdrawal of the causative agent if possible, and general supportive care.
authors.affiliation: Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA.
authors.forename: Laura
authors.initials: L
authors.lastname: Adang
authors.affiliation: Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Berger
keywords: JC virus; Progressive multifocal leukoencephalopathy; demyelination; highly active antiretroviral therapy; immunocompromised